| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/19/2014 | CN102311448B Thieno-pyrimidone DPP-IV (dipeptidyl peptidase) inhibitor |
| 02/19/2014 | CN102286586B Method for preparing oligopeptide of snake meat |
| 02/19/2014 | CN102276726B Fusion protein of hepatocyte growth factor receptor active group |
| 02/19/2014 | CN102166228B A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| 02/19/2014 | CN102125695B Polyglutamate-amino acid conjugates and methods |
| 02/19/2014 | CN102050879B Anti-human CD20 humanized antibody and preparation method and application thereof |
| 02/19/2014 | CN102007104B The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof |
| 02/18/2014 | USRE44768 Rapamycin hydroxyesters |
| 02/18/2014 | US8653252 Short interfering RNA (siRNA) analogues |
| 02/18/2014 | US8653133 Crystalline ingenol mebutate |
| 02/18/2014 | US8653117 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof |
| 02/18/2014 | US8653092 Tetrahydro-pyrido-pyrimidine derivatives |
| 02/18/2014 | US8653077 Inhibitors of human phosphatidylinositol 3-kinase delta |
| 02/18/2014 | US8653064 Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| 02/18/2014 | US8653050 Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| 02/18/2014 | US8653039 Peptide based inhibition of caPCNA interaction in cancer |
| 02/18/2014 | US8652839 HM1.24—utilizing cancer vaccines |
| 02/18/2014 | US8652807 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 02/18/2014 | US8652479 Antibody-drug conjugates and methods |
| 02/18/2014 | CA2743264C Tetrasubstituted pyridazines hedgehog pathway antagonists |
| 02/18/2014 | CA2726987C Stat3 inhibitors |
| 02/18/2014 | CA2624492C Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 02/18/2014 | CA2576627C Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| 02/18/2014 | CA2570213C Alpha-helical mimetics |
| 02/18/2014 | CA2564076C Chemical linkers and conjugates thereof |
| 02/18/2014 | CA2563831C Monocyclic heterocycles as kinase inhibitors |
| 02/18/2014 | CA2529244C Rapamycin resistant t cells and therapeutic uses thereof |
| 02/18/2014 | CA2507898C Immunoglobulin variants and uses thereof |
| 02/18/2014 | CA2454756C Methods and compounds for the targeting of protein to exosomes |
| 02/18/2014 | CA2429814C Rna interference mediating small rna molecules |
| 02/13/2014 | WO2014026198A1 Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| 02/13/2014 | WO2014026143A1 Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof |
| 02/13/2014 | WO2014026125A1 Pyrazine derivatives as fgfr inhibitors |
| 02/13/2014 | WO2014025960A1 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| 02/13/2014 | WO2014025890A1 Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids |
| 02/13/2014 | WO2014025828A1 Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| 02/13/2014 | WO2014025807A1 Pharmaceutical compositions comprising l-leucovorin |
| 02/13/2014 | WO2014025759A1 Iap antagonists |
| 02/13/2014 | WO2014025688A1 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| 02/13/2014 | WO2014025679A1 Process for the preparation of c-fms kinase inhibitors |
| 02/13/2014 | WO2014025486A1 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
| 02/13/2014 | WO2014025192A1 Pharmaceutical composition comprising paeonia japonica extract as active ingredient for treating uterine leiomyoma |
| 02/13/2014 | WO2014025191A1 Novel tetrazolo hydrazine derivatives and pharmaceutical composition comprising same as active ingredient for preventing or treating cancer |
| 02/13/2014 | WO2014025128A1 N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer |
| 02/13/2014 | WO2014024984A1 Hydrogen mixed gas supply device for medical purposes |
| 02/13/2014 | WO2014024965A1 Antigen peptide originated from t790m point-mutated sequence of epidermal growth factor receptor |
| 02/13/2014 | WO2014024168A1 Polymeric crown ether derivatives used in the treatment of proliferative diseases, in particular cancer |
| 02/13/2014 | WO2014024164A1 Process for the preparation of pemetrexed and lysin salt thereof |
| 02/13/2014 | WO2014024077A1 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS |
| 02/13/2014 | WO2014023976A1 Prophylactic and nutraceutical therapy |
| 02/13/2014 | WO2014023813A1 Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
| 02/13/2014 | WO2014023791A1 Treatment of drug resistance in hormone-sensitive cancer |
| 02/13/2014 | WO2014023754A1 Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac |
| 02/13/2014 | WO2014023732A1 Niclosamide and its derivatives for use in the treatment of solid tumors |
| 02/13/2014 | WO2014023709A1 Asgpr antibodies and uses thereof |
| 02/13/2014 | WO2014023679A1 Composition comprising two antibodies engineered to have reduced and increased effector function |
| 02/13/2014 | WO2014023643A1 Multitarget faah and cox inhibitors and therapeutical uses thereof |
| 02/13/2014 | WO2014023390A2 (aza-)isoquinolinone derivatives |
| 02/13/2014 | WO2014023385A1 Pyridopyrimidine derivatives as protein kinase inhibitors |
| 02/13/2014 | WO2014023329A1 Niclosamide and its derivatives for use in the treatment of solid tumors |
| 02/13/2014 | WO2014023325A1 Multitarget faah and cox inhibitors and therapeutical uses thereof |
| 02/13/2014 | WO2014023271A1 Casein kinase 1 inhibitors for the treatment of b-cell chronic lymphocytic|leukemia |
| 02/13/2014 | WO2014023083A1 PI3Kδ INHIBITOR |
| 02/13/2014 | WO2014023081A1 Artemisinin derivatives, preparation process and use thereof |
| 02/13/2014 | WO2014023063A1 High efficiency telomerase inhibitor and application of same in antitumor drug |
| 02/13/2014 | WO2014023027A1 Erlotinib hydrochloride polymorph and preparation method therefor |
| 02/13/2014 | WO2014022924A1 A method for the induction of an immune response |
| 02/13/2014 | WO2014022879A1 Compounds for the treatment of mtor pathway related diseases |
| 02/13/2014 | WO2013190569A3 Novel salts of sunitinib and preparation thereof |
| 02/13/2014 | WO2013188750A3 Substituted macrocyclic compounds having proteasome inhibitory activity |
| 02/13/2014 | US20140046287 Microfabricated nanopore device for sustained release of therapeutic agent |
| 02/13/2014 | US20140045916 Splice-region antisense composition and method |
| 02/13/2014 | US20140045837 9-Substituted 8-Oxoadenine Compound |
| 02/13/2014 | US20140045794 Phosphonate Compounds |
| 02/13/2014 | US20140045749 Growth factor complex |
| 02/13/2014 | US20140044753 Composition containing inorganic nanoparticles as an active ingredient for preventing or treating of angiogenesis-related diseases |
| 02/13/2014 | US20140044669 Cyclodextrin-based polymers for therapeutics delivery |
| 02/13/2014 | DE102010006245B4 Mayamycin-Verbindungen, Verfahren zu deren Herstellung, deren Verwendungen und diese enthaltendes kosmetisches Produkt Mayamycin compounds, processes for their preparation, their uses and these cosmetic product containing |
| 02/12/2014 | EP2696203A2 Tumor cell-derived microvesicles |
| 02/12/2014 | EP2695942A1 microRNAs in therapy and diagnostic of cancer |
| 02/12/2014 | EP2695895A1 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 02/12/2014 | EP2695884A1 Camptothecin derivatives having anti-tumor activity |
| 02/12/2014 | EP2695874A1 Myrtucommulone analogues |
| 02/12/2014 | EP2695617A2 Vitamin D glycosides and sulfates for treating intestinal diseases |
| 02/12/2014 | EP2694660A1 Efficient protein expression in vivo using modified rna (mod-rna) |
| 02/12/2014 | EP2694549A1 Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| 02/12/2014 | EP2694519A1 Novel heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
| 02/12/2014 | EP2694513A1 Pyrazolo pyrimidine derivatives |
| 02/12/2014 | EP2694511A1 Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
| 02/12/2014 | EP2694510A1 Imidazopyridazines as akt kinase inhibitors |
| 02/12/2014 | EP2694509A1 Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
| 02/12/2014 | EP2694508A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| 02/12/2014 | EP2694500A1 Substituted imidazopyridines and intermediates thereof |
| 02/12/2014 | EP2694498A1 Aminopyrazine compounds useful as inhibitors of tra kinase |
| 02/12/2014 | EP2694496A1 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| 02/12/2014 | EP2694487A1 G-quadruplex stabilising agent |
| 02/12/2014 | EP2694475A1 Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| 02/12/2014 | EP2694117A1 Polymalic acid based nanoconjugates for imaging |
| 02/12/2014 | EP2694113A2 Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics |
| 02/12/2014 | EP2694111A1 Antibody-drug conjugates |